



ROOTED IN SUCCESS

BETAFERON

June 2010 **ISSUE 17**

Showcasing Bayer's Commitment to the Treatment of MS: Berlin, 2010

Betaferon at European Neurological Society (ENS)

This year, the Twentieth Meeting of the European Neurological Society (ENS) took place in Bayer's home city of Berlin, Germany, from June 19-23. The meeting brought more than 2000 experts together and featured more than 700 abstracts, including six Betaferon presentations, one platform presentation, and five posters.

"This year's meeting was an opportunity to reinforce Betaferon as a first-line therapy in early MS and to highlight Bayer's commitment to the treatment of MS right here in the city of our headquarters," said Leslie Donato, VP Neurology/Global Brand Team Head for Betaferon.

The platform presentation was focused on the findings from a new analysis of the BEYOND study and was presented by the study's principal investigator, Dr. Massimo Filippi, Director, Neuroimaging Research Unit, Scientific Institute and University San Raffaele, Milan, Italy. The study showed that treatment with Betaferon affected the development of permanent black holes to a similar or better extent versus Copaxone in patients with MS. The proportion of newly active brain lesions that converted to permanent black holes for Betaferon and Copaxone was similar; however, Betaferon



demonstrated a 30-percent mean reduction in the number of newly active brain lesions converting into permanent black holes versus Copaxone. These data support Betaferon's neuroprotective benefits and are important to our early treatment story. The findings were also presented earlier this year during AAN.

Further data from two observational studies, CogniCIS and CogniMS (also presented during last year's ECTRIMS meeting), demonstrated aspects of MS early in the disease and showed that depression and

fatigue occur alongside cognitive deficits. Dawn Langdon, PhD, Neuropsychology Lead and Reader in Neuropsychology, Royal Holloway, University of London, United Kingdom, and lead investigator of CogniCIS and CogniMS, presented the findings during two poster presentations at the congress.

Two posters on survival rates and one on NABs data were also presented during ENS this year. These studies on survival data pave the way for our upcoming presentation of survival data from the 20-year LTF study planned for ECTRIMS later this year.